Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Can-Fite BioPharma ( (CANF) ) has provided an update.
On June 23, 2025, Can-Fite BioPharma Ltd. attempted to hold its Annual General Meeting of Shareholders, but it was adjourned due to a lack of quorum. The meeting is rescheduled to reconvene on June 30, 2025, at the company’s offices in Ramat Gan, Israel. This delay in the annual meeting may impact the company’s governance timeline and decision-making processes, potentially affecting stakeholders’ expectations.
The most recent analyst rating on (CANF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
Can-Fite BioPharma’s overall stock score reflects significant financial challenges and a bearish technical outlook. The company’s negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company based in Israel, primarily focused on developing small molecule drugs that address inflammatory, cancer, and liver diseases. The company leverages its expertise in the pharmaceutical industry to target specific market needs in these therapeutic areas.
Average Trading Volume: 216,279
Technical Sentiment Signal: Sell
Current Market Cap: $14.65M
Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.